AngioDynamics (NASDAQ:ANGO) Stock Unloaded Rep. Debbie Wasserman Schultz

Representative Debbie Wasserman Schultz (D-Florida) recently sold shares of AngioDynamics, Inc. (NASDAQ:ANGO). In a filing disclosed on October 24th, the Representative disclosed that they had sold between $1,001 and $15,000 in AngioDynamics stock on October 20th.

Representative Debbie Wasserman Schultz also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Controladora Vuela Compania de Aviacion (NYSE:VLRS) on 9/29/2025.
• Sold $1,001 – $15,000 in shares of Berry (NASDAQ:BRY) on 9/15/2025.
• Purchased $1,001 – $15,000 in shares of Stratasys (NASDAQ:SSYS) on 8/15/2025.
• Purchased $1,001 – $15,000 in shares of Ichor (NASDAQ:ICHR) on 8/5/2025.

AngioDynamics Trading Down 0.4%

Shares of AngioDynamics stock opened at $12.29 on Tuesday. The company has a fifty day moving average price of $10.85 and a 200 day moving average price of $9.97. AngioDynamics, Inc. has a twelve month low of $6.57 and a twelve month high of $13.50. The stock has a market cap of $506.35 million, a price-to-earnings ratio of -15.76 and a beta of 0.78.

AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings data on Thursday, October 2nd. The medical instruments supplier reported ($0.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.02. The company had revenue of $75.71 million during the quarter, compared to analysts’ expectations of $72.69 million. AngioDynamics had a negative net margin of 10.67% and a negative return on equity of 3.16%. The firm’s revenue for the quarter was up 12.1% on a year-over-year basis. During the same period in the prior year, the company posted ($0.11) EPS. AngioDynamics has set its FY 2026 guidance at -0.330–0.230 EPS. Analysts forecast that AngioDynamics, Inc. will post -0.37 earnings per share for the current year.

Institutional Investors Weigh In On AngioDynamics

Institutional investors have recently modified their holdings of the stock. State of Alaska Department of Revenue acquired a new stake in AngioDynamics during the third quarter worth about $25,000. State of Wyoming acquired a new stake in AngioDynamics during the second quarter worth about $31,000. Tower Research Capital LLC TRC raised its stake in AngioDynamics by 359.0% during the second quarter. Tower Research Capital LLC TRC now owns 5,457 shares of the medical instruments supplier’s stock worth $54,000 after acquiring an additional 4,268 shares during the period. Raymond James Financial Inc. acquired a new stake in AngioDynamics during the second quarter worth about $90,000. Finally, Cerity Partners LLC raised its stake in AngioDynamics by 22.0% during the first quarter. Cerity Partners LLC now owns 12,929 shares of the medical instruments supplier’s stock worth $121,000 after acquiring an additional 2,333 shares during the period. Institutional investors and hedge funds own 89.43% of the company’s stock.

Insider Activity

In other AngioDynamics news, CEO James C. Clemmer acquired 10,000 shares of the company’s stock in a transaction that occurred on Thursday, October 9th. The shares were purchased at an average price of $11.15 per share, for a total transaction of $111,500.00. Following the completion of the purchase, the chief executive officer directly owned 882,529 shares in the company, valued at $9,840,198.35. The trade was a 1.15% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Lawrence T. Weiss acquired 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 21st. The shares were acquired at an average price of $11.81 per share, for a total transaction of $118,100.00. Following the purchase, the senior vice president owned 93,597 shares of the company’s stock, valued at $1,105,380.57. This trade represents a 11.96% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders have purchased 20,890 shares of company stock worth $239,532. 6.00% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities analysts have weighed in on ANGO shares. Weiss Ratings reissued a “sell (d-)” rating on shares of AngioDynamics in a research report on Wednesday, October 8th. Lake Street Capital started coverage on shares of AngioDynamics in a research report on Wednesday, July 16th. They issued a “buy” rating and a $24.00 price objective for the company. Wall Street Zen cut shares of AngioDynamics from a “buy” rating to a “hold” rating in a research report on Saturday, October 4th. HC Wainwright reissued a “buy” rating and issued a $16.00 price objective on shares of AngioDynamics in a research report on Wednesday, July 16th. Finally, Canaccord Genuity Group upped their target price on shares of AngioDynamics from $17.00 to $18.00 and gave the company a “buy” rating in a research note on Friday, October 3rd. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $19.33.

About Representative Wasserman Schultz

Debbie Wasserman Schultz (Democratic Party) is a member of the U.S. House, representing Florida’s 25th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

Wasserman Schultz (Democratic Party) is running for re-election to the U.S. House to represent Florida’s 25th Congressional District. She declared candidacy for the 2026 election.

Debbie Wasserman Schultz was born in Forest Hills, New York. Wasserman Schultz graduated from Half Hollow Hills High School East in 1984. She earned a B.A. and M.A. from the University of Florida in 1988 and 1990, respectively. Wasserman Schultz’s career experience includes working as a staffer to former U.S. Representative Peter Deutsch.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.